Back to Search

JAE KIM, M.D.

M.D.

Gastroenterology Physician

NPI: 1861578759Individual

Specialties, Licenses & Credentials

Gastroenterology PhysicianPrimary

Internal Medicine — Gastroenterology

Code: 207RG0100X

73759(AZ)

Clinical Trials (1)

1
Linked Trials
0
Recruiting
0
With Results

Risankizumab Long-term Remission Study

NCT04630652ACTIVE_NOT_RECRUITINGPHASE4PRINCIPAL_INVESTIGATOR

Research & Publications (20)

Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Via practice · 9 locations total

Address
145 S 79th St Ste 35
Chandler, AZ 85226

Locations (9)

Practice Location

145 S 79th St Ste 35, Chandler, AZ
(480) 856-8252

Practice Location

1125 S ALMA SCHOOL RD STE 100, CHANDLER, AZ
(480) 550-6089

Practice Location

4545 N HUNT HWY, FLORENCE, AZ
(520) 868-3333

Practice Location

3920 S ROME ST, GILBERT, AZ
(480) 597-4778

Practice Location

10238 E HAMPTON AVE STE 205, MESA, AZ
(480) 856-8252

Practice Location

1301 S CRISMON RD, MESA, AZ
(480) 358-6100

Practice Location

37200 N Gantzel Rd Ste 100, Queen Creek, AZ
(480) 307-6741

Practice Location

37000 N GANTZEL RD, QUEEN CREEK, AZ
(480) 394-4000

Practice Location

1500 S MILL AVE, TEMPE, AZ
(480) 784-5500

Quick Facts

NPI
1861578759
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
9
Clinical Trials
1
Publications
20

Are you this provider?

Claim Your Profile